Chronoscale Corp (CHRN) Stock AnalysisCHRNChronoscale Corp

ChronoScale Corporation, formerly Ekso Bionics Holdings, Inc., designs, develops, and markets exoskeleton products. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The Company operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. It enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. It assists people to perform challenging repetitive tasks for extended periods. It operates in the Healthcare sector.

Currently, Ekso Bionics Holdings, Inc. (CHRN) is not a strong buy. The stock is trading at $18.59, which is significantly lower than the analyst price target of $32, indicating potential upside. However, the RSI is at 36.299, suggesting it is nearing oversold territory but not yet a clear buy signal. The company has also reported a substantial net income loss of -7261000.00 USD in the latest quarter, which raises concerns about its financial health. The main risk is the declining gross margin, which fell to 50.16% in Q1 2026, indicating potential profitability issues.